The Section of Hematology/Oncology has a very robust and successful clinical research program. Currently over 250 industry sponsored clinical trials are available to patients with:
- Lung Cancer
- Head and neck cancer
- Breast cancer
- GI Cancer
- Genitourinary Cancer
- Other solid tumors.
In addition, the Section of Hematology/Oncology is one of only a handful of institutions in the country to conduct clinical trials in Phase I, Phase II, and Phase III drug development. A Phase I trial is the first step for physicians to determine whether a potential drug can be tolerated. Presently the Section is the recipient of a Phase I grant that provides novel cancer therapies to patients who have not responded to established therapies. Phase II trials occur after a potential treatment is found to be tolerated in Phase I trials. Our clinical researchers study the effectiveness of the treatment on a specific type of cancer in a small group of patients. Phase III trials occur after Phase II generally in larger groups of patients to compare the experimental treatment’s effectiveness against standard therapy for a particular type of cancer. We are the headquarters for CALGB, Cancer and Leukemia Group B, a national network of 29 university medical centers, over 225 community hospitals and more than 3,000 oncology specialists who collaborate in clinical research studies
The main objective of our clinical research initiative is to identify less toxic and more effective treatment regimens for all types of cancers. As a result, we have discovered many innovative and cutting edge cancer therapies which often are not available at other institutions.
The majority of the faculty is dedicated to clinical research efforts and are assisted by a team of research nurses, data and regulatory coordinators who serve to facilitate data management of ongoing trials, organization of responsibilities of ancillary study staff, and coordination of follow up for patients involved in ongoing clinical trials.